Clinical Trial: 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025512) titled '177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia' on June 06.

Brief Summary: To control mCRPC that has spread to the bone marrow. The safety and effects of this treatment will also be studied.

Study Start Date: Dec. 03, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Castration Resistant Prostate Cancer Bone Marrow Cytopenia

Intervention: DRUG: 177Lu-PSMA-617

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content Services with permission from Health Daily Digest....